Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Facts and hopes for PET imaging-derived immunotherapy biomarkers
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-24-1427
Current immunotherapies have brought major progress in cancer treatments, but not all patients benefit. Therefore, insight into reasons for treatment failure and optimal biomarkers for patient selection are warranted. Current approved biomarkers for cancer immunotherapy do not provide insight into characteristics across tumor lesions in a patient or their heterogeneity. Here, whole-body positron emission tomography (PET) imaging with specific tracers may provide support. Moreover, the biodistribution of cell therapies and complex molecules, such as bispecific antibodies, can be visualized by PET imaging, and repeat PET imaging allows to...
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring
Published in: Endocrine practice
Access to document
10.1016/j.eprac.2024.09.013
document
OBJECTIVES: During intensive hematological care, patients are exposed to high-dose chemotherapy, corticosteroids, immunosuppressants and total parenteral nutrition. Combined with physiological stress and increased release of cytokines and hormones, this can lead to dysglycemia, which is associated with adverse clinical outcomes. This prospective study aims to investigate continuous glucose monitoring (CGM) to identify dysglycemia during intensive hematological care. METHODS: Patients receiving chimeric antigen receptor (CAR) T-cell therapy, allogeneic or autologous stem cell transplantation (SCT) were eligible. Throughout the study, glucose levels were concurrently monitored using CGM and point-of-care (POC)...
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Published in: The Lancet
Access to document
10.1016/S0140-6736(24)00184-3
document
Background: Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT. Methods: The open-label, randomised, three-arm, parallel-group, superiority TRIANGLE trial was performed in 165 secondary...
Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trneny, Vibeke Vergote, Ofer Shpilberg, Maria Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Stephan Stilgenbauer, Andrea Kerkhoff, Ron D. Jachimowicz, Melania Celli, Georg Hess, Luca ArcainiCarlo Visco, Tom van Meerten, Stefan Wirths, Pier Luigi Zinzani, Urban Novak, Peter Herhaus, Fabio Benedetti, Kristina Sonnevi, Christine Hanoun, Matthias Hänel, Judith Dierlamm, Christiane Pott, Wolfram Klapper, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
Published in: Experimental Hematology & Oncology
Access to document
10.1186/s40164-024-00501-x
document
BACKGROUND: VISTA is a well-known immune checkpoint in T cell biology, but its role in innate immunity is less established. Here, we investigated the role of VISTA on anticancer macrophage immunity, with a focus on phagocytosis, macrophage polarization and concomitant T cell activation. METHODS: Macrophages, differentiated from VISTA overexpressed THP-1 cells and cord blood CD34 + cell-derived monocytes, were used in phagocytosis assay using B lymphoma target cells opsonized with Rituximab. PBMC-derived macrophages were used to assess the correlation between phagocytosis and VISTA expression. qRT-PCR, flow cytometry, and...
Yusheng Lin, Ghizlane Choukrani, Lena Dubbel, Lena Rockstein, Jimena Alvarez Freile, Yuzhu Qi, Valerie Wiersma, Hao Zhang, Karl-Wilhelm Koch, Emanuele Ammatuna, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma
Published in: Blood cancer journal
Access to document
10.1038/s41408-024-01022-w
document
Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV-dynamics, between pre-apheresis (baseline) and pre-lymphodepleting chemotherapy (pre-LD) MATV, on CAR T-cell outcomes and toxicities in patients with r/r LBCL. MATVs were calculated semi-automatically at baseline (n = 74) and pre-LD (n = 68) in patients with r/r LBCL who received axicabtagene ciloleucel. At baseline, patients with a low MATV (< 190 cc) had a better time to...